AtaiBeckley (NASDAQ:ATAI) saw its common stock added to the NASDAQ Biotechnology Index (NBI) prior to the market open on Dec. 22, 2025, marking a significant milestone in the company’s evolution as a leader in neuropsychiatric drug development.
Novo Nordisk A/S (NASDAQ:NVO) received U.S. Food and Drug Administration approval on Monday for the first oral version of its blockbuster weight-loss medication Wegovy, setting the stage for a January launch that will bypass traditional insurance hurdles
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) received marketing authorization in Japan for their blockbuster drug Dupixent to treat severe asthma in children aged 6 to 11.
Chimeric Therapeutics (ASX:CHM) has secured $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 clinical trial through the end of Phase 1.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have secured their tenth Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for ENHERTU, marking a pivotal expansion into the early-stage treatment of breast cancer.
Indivior (NASDAQ:INDV) has announced its inclusion in the S&P SmallCap 600 index, effective December 22, 2025.
The company stated that this milestone aligns its capital markets presence with a sharpened U.S. business profile and supports the growth of SUBLOCADE, its first-in-class long-acting injectable for moderate to severe opioid use disorder.
NeuroSense Therapeutics (NASDAQ:NRSN) reported on Monday the successful completion of a safety analysis for its Phase 2 NST-AD-001 study, a critical step in the company's efforts to repurpose its lead ALS candidate, PrimeC, for the treatment of Alzheimer’s disease.
Greenwich LifeSciences (NASDAQ:GLSI) provided a comprehensive year-end update on Monday for its pivotal Phase III clinical trial, FLAMINGO-01.
The trial is evaluating GLSI-100, a Fast Track-designated immunotherapy designed to prevent breast cancer recurrence in HER2-positive patients.
KalVista Pharmaceuticals (NASDAQ:KALV) has received marketing and manufacturing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for EKTERLY (sebetralstat), establishing it as the first and only oral on-demand treatment for hereditary angioedema (HAE) in the country.
Alvotech (NASDAQ:ALVO) achieved a significant milestone in the competitive biologics market on Monday, announcing the European debut of Gobivaz, the first biosimilar to the blockbuster inflammatory drug Simponi to reach the market anywhere in the world.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have secured their tenth Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration for ENHERTU, marking a pivotal step in moving the blockbuster treatment into earlier, potentially curative stages of breast cancer.
